A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

INTRODUCTION: The objective of this study was to determine whether the addition of ramucirumab to first-line paclitaxel–carboplatin chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) resulted in a 6-month progression-free survival (PFS) rate that compares favorably with the hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Camidge, D. Ross, Berge, Eamon M., Doebele, Robert C., Ballas, Marc S., Jahan, Thierry, Haigentz, Missak, Hoffman, David, Spicer, James, West, Howard, Lee, Pablo, Yang, Ling, Joshi, Adarsh, Gao, Ling, Yurasov, Sergey, Mita, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165478/
https://www.ncbi.nlm.nih.gov/pubmed/25170639
http://dx.doi.org/10.1097/JTO.0000000000000273

Ejemplares similares

Ejemplares similares